iRhythm Technologies (NASDAQ:IRTC) EVP Minang Turakhia Sells 4,027 Shares

iRhythm Technologies (NASDAQ:IRTC) EVP Minang Turakhia sold 4,027 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $128.45, for a total transaction of $517,268.15. Following the sale, the executive vice president owned 54,906 shares in the company, valued at approximately $7,052,675.70. This trade represents a 6.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Minang Turakhia also recently made the following trade(s):

• On Wednesday, February 25th, Minang Turakhia sold 7,804 shares of iRhythm Technologies stock. The stock was sold at an average price of $135.42, for a total transaction of $1,056,817.68.

iRhythm Technologies Stock Down 2.0%

IRTC opened at $125.85 on Wednesday. The business’s fifty day simple moving average is $159.40 and its 200 day simple moving average is $170.14. iRhythm Technologies has a 52 week low of $92.52 and a 52 week high of $212.00. The company has a quick ratio of 4.48, a current ratio of 4.63 and a debt-to-equity ratio of 4.25. The stock has a market cap of $4.07 billion, a PE ratio of -89.89 and a beta of 1.09.

iRhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings data on Thursday, February 19th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.27. The firm had revenue of $208.89 million during the quarter, compared to analysts’ expectations of $202.61 million. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.The company’s revenue for the quarter was up 27.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.04) EPS. As a group, research analysts expect that iRhythm Technologies will post -1.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On iRhythm Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new position in iRhythm Technologies in the second quarter valued at about $3,578,000. Federated Hermes Inc. grew its stake in shares of iRhythm Technologies by 45.4% during the 3rd quarter. Federated Hermes Inc. now owns 70,401 shares of the company’s stock valued at $12,108,000 after purchasing an additional 21,977 shares during the period. Osaic Holdings Inc. grew its stake in shares of iRhythm Technologies by 507.3% during the 2nd quarter. Osaic Holdings Inc. now owns 9,292 shares of the company’s stock valued at $1,431,000 after purchasing an additional 7,762 shares during the period. Jump Financial LLC purchased a new stake in shares of iRhythm Technologies during the 2nd quarter valued at about $9,668,000. Finally, Walleye Capital LLC bought a new position in shares of iRhythm Technologies in the 2nd quarter worth approximately $11,366,000.

More iRhythm Technologies News

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Company guidance: iRhythm updated FY‑2026 revenue guidance to $870.0M–$880.0M, noticeably above the consensus (~$817.3M). Higher top‑line guidance is a positive signal for growth and revenue cadence even though EPS guidance was not specified in the release.
• Neutral Sentiment: Analyst/market note: Coverage is shifting as targets are being reset while management’s guidance holds — a thematic piece that explains why price targets and sentiment may be changing even with stronger revenue guidance. How The iRhythm Holdings (IRTC) Story Is Shifting As Targets Reset And Guidance Holds
• Negative Sentiment: Insider selling: Multiple senior execs sold shares on March 2 — including the CAO, several EVPs and other insiders — totaling ~17,826 shares for roughly $2.29M in proceeds (average price ≈ $128.44). Each reported a mid-single-digit percentage reduction in their holdings; insiders still retain substantial stakes but the clustered selling can be perceived negatively by the market. Representative SEC filing: Insider Form 4

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. JPMorgan Chase & Co. reduced their target price on shares of iRhythm Technologies from $240.00 to $215.00 and set an “overweight” rating on the stock in a report on Friday, February 20th. Canaccord Genuity Group dropped their target price on iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating for the company in a report on Friday, February 20th. Robert W. Baird dropped their price objective on iRhythm Technologies from $220.00 to $200.00 and set an “outperform” rating for the company in a research note on Friday, February 20th. Evercore raised shares of iRhythm Technologies from an “in-line” rating to an “outperform” rating and increased their price target for the company from $194.00 to $210.00 in a research report on Monday, January 5th. Finally, Truist Financial reissued a “buy” rating and issued a $200.00 target price (down from $215.00) on shares of iRhythm Technologies in a research note on Friday, February 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, iRhythm Technologies presently has an average rating of “Moderate Buy” and an average price target of $211.62.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.